RALA peptide
Based on 1 Customer Validation
RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.38%
- CAS. Nr.: 1613231-49-4
- Formel: C144H248N54O35S
- Molecular Weight:3327.92
-
Speicherung:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Nanoparticles formed by RALA peptide (mass ratio of 10:1 to bisphosphonate; 6 h in vitro treatment and 72 h culture) and bisphosphonate significantly enhances the antiproliferative activity against PC3 prostate cancer cells and MDA-MB-231 breast cancer cells[1].
Nanoparticles formed by RALA peptide (mass ratio of 5:1 to α-TCP; 24 h in vitro transfection and 28 d culture) combined with α-TCP, promotes the expression and deposition of type I collagen in MG-63 osteoblasts and enhances the extracellular matrix mineralization of porcine mesenchymal stem cells[2][3].
After RALA peptide (mass ratio of 5:1 to α-TCP; cultured in vitro for 2-4 weeks) deliveres to mesenchymal stem cells, significantly upregulates the expression of BMP-2 and core osteogenic genes and accelerated the mineralization process in the engineered hydrogel[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
RALA peptide (composite α-TCP nanoparticles; subcutaneous implantation; single implantation; in vivo implantation for 8 weeks) promotes osteogenic differentiation and vascularization to achieve efficient bone tissue regeneration in Balb/C nude mouse model, induces bone tissue formation in hydrogel loaded with mesenchymal stem cells, without significantly different in mineralization volume from that in the growth factor delivery group, indicating that RALA-mediated α-TCP delivery can replace growth factors to promote bone regeneration in vivo[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1613231-49-4
-
Appearance Solid
-
Molecular Weight 3327.92
-
Formel C144H248N54O35S
-
Color White to off-white
-
Sequence
Trp-Glu-Ala-Arg-Leu-Ala-Arg-Ala-Leu-Ala-Arg-Ala-Leu-Ala-Arg-His-Leu-Ala-Arg-Ala-Leu-Ala-Arg-Ala-Leu-Arg-Ala-Cys-Glu-Ala
-
Sequence Shortening
WEARLARALARALARHLARALARALRACEA
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (15.02 mM; ultrasonic and adjust pH to 2 with 1M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Massey AS, et al. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. Mol Pharm. 2016 Apr 4;13(4):1217-28. [Content Brief]
[2]. O'Doherty M, et al. Improving the Intercellular Uptake and Osteogenic Potency of Calcium Phosphate via Nanocomplexation with the RALA Peptide. Nanomaterials (Basel). 2020 Dec 7;10(12):2442 [Content Brief]
[3]. Sathy BN, et al. RALA complexed α-TCP nanoparticle delivery to mesenchymal stem cells induces bone formation in tissue engineered constructs in vitro and in vivo. J Mater Chem B. 2017 Mar 7;5(9):1753-1764. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3005 mL | 1.5024 mL | 3.0049 mL | 7.5122 mL |
| 5 mM | 0.0601 mL | 0.3005 mL | 0.6010 mL | 1.5024 mL | |
| 10 mM | 0.0300 mL | 0.1502 mL | 0.3005 mL | 0.7512 mL | |
| 15 mM | 0.0200 mL | 0.1002 mL | 0.2003 mL | 0.5008 mL |
RALA peptide Related Classifications
HY-P5284 Related Classifications
Powered by Bioz